Efficacy of tenofovir disoproxil fumarate at 240 weeks in patients with chronic hepatitis B with high baseline viral load - PubMed (original) (raw)

Randomized Controlled Trial

doi: 10.1002/hep.26277. Epub 2013 May 3.

Zahary Krastev, Andrzej Horban, Jörg Petersen, Jan Sperl, Phillip Dinh, Eduardo B Martins, Leland J Yee, John F Flaherty, Kathryn M Kitrinos, Vinod K Rustgi, Patrick Marcellin

Affiliations

Free PMC article

Randomized Controlled Trial

Efficacy of tenofovir disoproxil fumarate at 240 weeks in patients with chronic hepatitis B with high baseline viral load

Stuart C Gordon et al. Hepatology. 2013 Aug.

Free PMC article

Abstract

We evaluated the antiviral response of patients with chronic hepatitis B (CHB) who had baseline high viral load (HVL), defined as having hepatitis B virus (HBV) DNA ≥ 9 log10 copies/mL, after 240 weeks of tenofovir disoproxil fumarate (TDF) treatment. A total of 641 hepatitis B e antigen (HBeAg)-negative and HBeAg-positive patients (129 with HVL) received 48 weeks of TDF 300 mg (HVL n = 82) or adefovir dipivoxil (ADV) 10 mg (HVL n = 47), followed by open-label TDF for an additional 192 weeks. Patients with confirmed HBV DNA ≥ 400 copies/mL on or after week 72 had the option of adding emtricitabine (FTC). By week 240, 98.3% of HVL and 99.2% of non-HVL patients on treatment achieved HBV DNA <400 copies/mL. Both groups had similar rates of histologic regression between baseline and week 240. Patients with HVL generally took longer to achieve HBV DNA <400 copies/mL than non-HVL patients, but by week 96, the percentages of patients with HBV DNA <400 copies/mL were similar in both groups. Among HVL patients, time to achieving HBV DNA <400 copies/mL was shorter among those initially receiving TDF, compared to ADV. No patient with baseline HVL had persistent viremia at week 240 or amino acid substitutions associated with TDF resistance.

Conclusion: CHB patients with HVL can achieve HBV DNA negativity with long-term TDF treatment, although time to HBV DNA <400 copies/mL may be longer, relative to patients with non-HVL.

Copyright © 2013 American Association for the Study of Liver Diseases.

PubMed Disclaimer

Figures

Figure 1

Figure 1

Time to viral negativity on the basis of baseline viral load. The proportion of patients with HBV high baseline viral load (≥9 log10 copies/mL) and non-high baseline viral load (<9 log10 copies/mL) who achieved HBV DNA <400 copies/mL during TDF long-term treatment. (A) Excludes patients who received FTC. (B) Includes patients who received FTC. Vertical bars represent 95% confidence intervals.

Figure 2

Figure 2

Viral load over time. Mean HBV DNA for patients with high baseline viral load (≥9 log10 copies/mL) and non-high baseline viral load (<9 log10 copies/mL) during TDF long-term treatment. (A) Excludes patients who received FTC. (B) Includes patients who received FTC. Vertical bars represent 95% confidence intervals.

Figure 3

Figure 3

Time to viral negativity on the basis of initial therapy. The proportion of patients with HBV high baseline viral load who reached HBV DNA <400 copies/mL after initial treatment with either TDF or ADV. (A) Excludes patients who received FTC. (B) Includes patients who received FTC. Vertical bars represent 95% confidence intervals.

Comment in

References

    1. Chen C-F, Lee W-C, Yang H-I, Chang H-C, Jen C-L, Iloeje UH, et al. Changes in serum levels of HBV DNA and alanine aminotransferase determine risk for hepatocellular carcinoma. Gastroenterology. 2011;141:1240–1248. 1248.e1-2. - PubMed
    1. Iloeje UH, Yang H-I, Su J, Jen C-L, You S-L, Chen C-J. Predicting cirrhosis risk based on the level of circulating hepatitis B viral load. Gastroenterology. 2006;130:678–686. - PubMed
    1. Chen C-J, Yang H-I, Su J, Jen C-L, You S-L, Lu S-N, et al. Risk of hepatocellular carcinoma across a biological gradient of serum hepatitis B virus DNA level. JAMA. 2006;295:65–73. - PubMed
    1. Buster EHCJ, Hansen BE, Lau GKK, Piratvisuth T, Zeuzem S, Steyerberg EW, et al. Factors that predict response of patients with hepatitis B e antigen-positive chronic hepatitis B to peginterferon-alfa. Gastroenterology. 2009;137:2002–2009. - PubMed
    1. Cooksley G, Manns M, Lau GKK, Liaw Y-F, Marcellin P, Chow C. Effect of genotype and other baseline factors on response to peginterferon alfa-2a (40 kDa) (Pegasys) in HBeAg-positive chronic hepatitis B: results from a large, randomised study. J Hepatol. 2005;42(Suppl 2):30–31.

Publication types

MeSH terms

Substances

LinkOut - more resources